Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Finn, Richard S.; Rugo, Hope S.; Dieras, Veronique C; Harbeck, Nadia; Im, Seock-Ah; Gelmon, Karen A.; Walshe, Janice Maria; Martin, Miguel; Chavez Mac Gregor, Mariana; Bananis, Eustratios; Gauthier, Eric Roland; Lu, Dongrui Ray; Kim, Sindy; Slamon, Dennis J.

doi:10.1200/jco.2022.40.17_suppl.lba1003

Cited by 171Advanced Breast Cancer TherapiesBreast Cancer Treatment StudiesPARP inhibition in cancer therapy

The DOI matches its Crossref record.

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Finn, Richard S., Rugo, Hope S., Dieras, Veronique C, Harbeck, Nadia, Im, Seock-Ah, Gelmon, Karen A., Walshe, Janice Maria, Martin, Miguel, Chavez Mac Gregor, Mariana, Bananis, Eustratios, Gauthier, Eric Roland, Lu, Dongrui Ray, Kim, Sindy, Slamon, Dennis J.·2022·Journal of Clinical Oncology

DOI 10.1200/jco.2022.40.17_suppl.lba1003

Open this paper in CoChat — free account

Abstract

LBA1003 Background: PAL was the first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved for ER+/HER2– ABC based on the randomized, phase 2 PALOMA-1 study. PALOMA-2 is a randomized, double-blind, phase 3 trial in first-line ER+/HER2– ABC that confirmed a clinically and statistically significant improvement in progression-free survival (PFS) with PAL+LET versus PBO+LET (median PFS, 27.6 vs 14.5 months; hazard ratio, 0.56 [95% CI, 0.46–0.69]; P<0.0001). At the time of the final PFS analysis, OS data were not mature. Herein, we report OS results. Methods: 666 postmenopausal women with ER+/HER2– ABC who had not received prior systemic therapy for advanced disease were randomized 2:1 to receive PAL (125 mg/d orally, 3/1 week schedule) plus LET (2.5 mg/d orally, continuously) or PBO+LET. The primary endpoint was investigator-assessed PFS and a key secondary endpoint was OS. Per study design, 390 OS events are required to have 80% power to detect a hazard ratio <0.74 at a significance level of 0.025 (1-sided) using a stratified log-rank test. The planned final OS analysis was conducted when the number of events required for the analysis was observed. Results: At data cut-off (November 15, 2021), with a median follow-up of 90 months, 43 patients (pts; 10%) remained on PAL+LET and 5 pts (2%) on PBO+LET. With 405 deaths, median OS (95% CI) was 53.9 months (49.8–60.8) in the PAL+LET arm and 51.2 months (43.7 –58.9) in the PBO+LET arm (hazard ratio, 0.956 [95% CI, 0.777–1.177]; stratified 1-sided P=0.3378). In this OS analysis, a proportion of pts were not available for follow-up (withdrew consent or lost to follow-up) and were censored: 21% in the PBO+LET arm versus 13% in the PAL+LET arm. A posthoc sensitivity analysis excluding these pts resulted in a median OS (95% CI) of 51.6 months (46.9–57.1) with PAL+LET and 44.6 months (37.0–52.3) with PBO+LET (hazard ratio, 0.869 [95% CI, 0.706–1.069]). Of the pts who discontinued study treatment, 81% in the PAL+LET arm and 88% in the PBO+LET arm received post-study systemic therapy; 12% and 27% of pts who discontinued received CDK4/6 inhibitor, respectively. In pts with disease-free interval (DFI) >12 months, median OS (95% CI) was 66.3 months (52.1–79.7) in the PAL+LET arm (n=179) and 47.4 months (37.7–57.0) in the PBO+LET arm (n=93); hazard ratio, 0.728 (95% CI, 0.528-1.005). No new safety findings were observed. Conclusions: PALOMA-2 met its primary endpoint of improving PFS but not the secondary endpoint of OS. Pts receiving PAL+LET had numerically longer OS compared to PBO+LET, but the results were not statistically significant. Funding: Pfizer Inc (NCT01740427) Clinical trial information: NCT01740427.

Integrity signals

Registry

Crossref · 10.1200/jco.2022.40.17_suppl.lba1003

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Palbociclib, in contrast to abemaciclib and ribociclib, has not shown a clinically meaningful or statistically significant difference in OS in the first- or second-line ABC setting or an invasive disease-free survival (IDFS) benefit in the EBC setting.
“which in contrast to abemaciclib and ribociclib, has not shown a clinically meaningful or statistically significant difference in OS in the firstor second-line ABC setting or an invasive disease-free survival (IDFS) benefit in the EBC setting.17,18,21,22”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [17]
Consistent differences in outcomes (OS and IDFS) have emerged across phase III studies of CDK4/6 inhibitors.
“consistent differences in outcomes (OS and IDFS) have emerged across phase III studies of these therapies”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [17]
The clinical relevance of the observed median OS improvement for palbociclib is less clear.
“while the clinical relevance of the observed median OS improvement for palbociclib is less clear.”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [17]
First-line palbociclib + letrozole failed to demonstrate a statistically significant improvement in overall survival over letrozole alone in postmenopausal patients in the PALOMA-2 trial.
“First-line palbociclib in combination with the nonsteroidal aromatase inhibitor (NSAI) letrozole failed to demonstrate a statistically significant improvement in OS over letrozole alone in postmenopausal patients in the PALOMA-2 trial (median OS [mOS], 53.9 vs. 51.2 months [hazard ratio (HR) 0.96; 95% CI 0.78–1.18; P = 0.34]) [9].”
From Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. (2023) · cites this paper as [9]

Still being checked.

Sorted by citations

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V. G., Aft, R., Agnese, D. M., Allison, K. H., Anderson, B. M., Burstein, H. J., Chew, H. K., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 469
Self-citation
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 290
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Cardoso, F., Paluch–Shimon, S., Schumacher-Wulf, E., de Matos, L. V., Gelmon, K. A., Aapro, M., Bajpai, J., Barrios, C. H., Bergh, J. C. S., Bergsten-Nordström, E., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103756 · Cited by 276
Self-citation
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
Goetz, M. P., Toi, M., Huober, J., Sohn, J., Trédan, O., Park, I. H., Campone, M., Chen, S.-C., Manso, L. M., Paluch-Shimon, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.013 · Cited by 238
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Huppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
Self-citation
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
Rugo, H. S., Brufsky, A., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., Cristofanilli, M., Torres, M. A., Curigliano, G., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00479-x · Cited by 126
Self-citation
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Sonke, G. S., van Ommen‐Nijhof, A., Wortelboer, N., van der Noort, V., Swinkels, A. C. P., Blommestein, H. M., Páez, C. G., Mol, L., Beeker, A., Beelen, K. J., et al. (2024) · Nature · doi:10.1038/s41586-024-08035-2 · Cited by 89
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01701-9 · Cited by 83
Self-citation
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Solís, M. C., Gil-Torralvo, A., Castilla, M. Á., Dominguez-Cejudo, M. A., Falcón, A., Benavent, M., Molina‐Pinelo, S., Ruíz-Borrego, M., & Bofill, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108488 · Cited by 83
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
Downton, T. D., Zhou, F. H., Segara, D., Jeselsohn, R. M., & Lim, E. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s380925 · Cited by 72
Advances in medical treatment of breast cancer in 2022
Zhai, J., Wu, Y., Ma, F., Kaklamani, V., & Xu, B. (2023) · Cancer Innovation · doi:10.1002/cai2.46 · Cited by 67
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
O'Sullivan, C. C., Clarke, R. C., Goetz, M. P., & Robertson, J. F. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2000 · Cited by 67
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti, C., Angelis, C. D., Bianchini, G., Malorni, L., Giuliano, M., Hamilton, E. P., Jeselsohn, R. M., Jhaveri, K. L., Curigliano, G., & Criscitiello, C. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102569 · Cited by 64
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Im, S., Gennari, A., Park, Y. H., Kim, J. H., Jiang, Z., Gupta, S., Fadjari, T. H., Tamura, K., Mastura, M. Y., Abesamis-Tiambeng, M. L. T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101541 · Cited by 62
Self-citation
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Zhou, F. H., Downton, T. D., Freelander, A., Hurwitz, J., Caldon, C. E., & Lim, E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1148792 · Cited by 58
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study
Goyal, R., Chen, H., Abughosh, S., Holmes, H. M., Candrilli, S. D., & Johnson, M. L. (2023) · Cancer · doi:10.1002/cncr.34675 · Cited by 49
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
Grinshpun, A., Tolaney, S. M., Burstein, H. J., Jeselsohn, R. M., & Mayer, E. L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00520-7 · Cited by 49
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Jhaveri, K. L., & Marmé, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102670 · Cited by 49
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
Kappel, C., Elliott, M. J., Kumar, V., Nadler, M. B., Desnoyers, A., & Amir, E. (2024) · Scientific Reports · doi:10.1038/s41598-024-53151-8 · Cited by 48
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
Jérusalem, G., Prat, A., Salgado, R., Reinisch, M., Saura, C., Ruíz-Borrego, M., Nikolinakos, P. G., Ades, F., Filian, J., Huang, N., et al. (2023) · The Breast · doi:10.1016/j.breast.2023.103580 · Cited by 46
CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis
Müller, C., Kiver, V. I. I., Solomayer, E., Wagenpfeil, G., Neeb, C., Blohmer, J., Abramian, A. V., Maass, N., Schütz, F., Kolberg‐Liedtke, C., et al. (2022) · Breast Care · doi:10.1159/000527917 · Cited by 44
Mechanisms of endocrine resistance in hormone receptor-positive breast cancer
Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1448687 · Cited by 43
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Mittal, A., Moltó, C., Tamimi, F., Schlam, I. M., Sammons, S. L., Tolaney, S. M., & Tarantino, P. (2023) · Cancers · doi:10.3390/cancers15072015 · Cited by 41
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry
Meegdes, M., Geurts, S. M. E., Erdkamp, F., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L., Peters, N. A. J. B., Tol, J., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100573 · Cited by 36
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
Thill, M., Kolberg‐Liedtke, C., Albert, U., Banys-Paluchowski, M. J., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Ditsch, N., Fallenberg, E. M., et al. (2023) · Breast Care · doi:10.1159/000531579 · Cited by 34
Self-citation
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
Lee, J. S., Hackbart, H., Cui, X., & Yuan, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411791 · Cited by 33
Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer
Ferro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 31
HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Jerzak, K. J., Bouganim, N., Brezden‐Masley, C., Edwards, S. J., Gelmon, K. A., Henning, J., Hilton, J. F., & Sehdev, S. R. (2023) · Current Oncology · doi:10.3390/curroncol30060411 · Cited by 31
Self-citation
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, S. R. D., Emde, A., Barrios, C. H., Srock, S., Neven, P., Martin, M., Cameron, D., Janni, W., & Gnant, M. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad045 · Cited by 30
Self-citation
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Nabieva, N., & Fasching, P. A. (2023) · Cancers · doi:10.3390/cancers15061763 · Cited by 29
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
Masurkar, P. P., Damgacioglu, H., Deshmukh, A. A., & Trivedi, M. V. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01245-y · Cited by 28
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad207 · Cited by 27
Self-citation
Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR ‐positive/ HER2 ‐negative metastatic breast cancer with real‐world data from the OPAL registry
Thill, M., Zahn, M., Welt, A., Nusch, A., Zaiss, M. R., Engelken, K., Kaltenecker, G., Ringwald, K. G., Gratzke, K., Dille, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35296 · Cited by 26
Self-citation
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Kahraman, S., Erul, E., Seyyar, M., Gümüşay, Ö., Bayram, E., Demirel, B. Ç., Acar, Ö., Aksoy, S., Baytemür, N. K., Şahin, E., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1287 · Cited by 26
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Antonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 26
Reporting on invasive lobular breast cancer in clinical trials: a systematic review
Baelen, K. V., Cauwenberge, J. V., Maetens, M., Beck, G., Camden, A., Chase, M.-C., Fraser, V. L., Freeney, S., Hutcheson, L., Levine, J. K., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00627-5 · Cited by 26
How I treat endocrine-dependent metastatic breast cancer
Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 25
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Ashai, N., & Swain, S. M. (2023) · Cancers · doi:10.3390/cancers15061855 · Cited by 25
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 24
Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 24
Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
Brufsky, A., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Rugo, H. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1237751 · Cited by 23
Self-citation
The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study
Al-Ziftawi, N. H., Elazzazy, S., Alam, M. F., Shafie, A. A., Hamad, A. A., Bbujassoum, S., & Ibrahim, M. I. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203684 · Cited by 23
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Prat, A., Solovieff, N., André, F., O’Shaughnessy, J., Cameron, D., Janni, W., Sonke, G. S., Yap, Y. S., Yardley, D. A., Partridge, A. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0561 · Cited by 22
Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way beyond
Nicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 23
The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis
Petrelli, F., Dottorini, L., Menna, G. D., Borgonovo, K., Parati, M. C., Rea, C. G., Ghilardi, M., Ghidini, A., & Luciani, A. (2023) · The Breast · doi:10.1016/j.breast.2023.05.002 · Cited by 21
Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database
Rugo, H. S., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Brufsky, A. (2023) · International Journal of Cancer · doi:10.1002/ijc.34748 · Cited by 20
Self-citation
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Shao, H., Zhao, M., Guan, A., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · BMC Medicine · doi:10.1186/s12916-023-03238-2 · Cited by 21
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
Brain, E. G. C., Chen, C., Simon, S., Pasupuleti, V., Pfitzer, K. V., & Gelmon, K. A. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01046-z · Cited by 20
Self-citation
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Ziyeh, S., Wong, L., & Basho, R. K. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01393-6 · Cited by 19
Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
Tang, H., Yeo, D., DeSouza, K., Ahmad, O., Shafiq, T., Ofor, O., Anand, A., Karim, S., Khan, S. N., & Madhusudan, S. (2023) · Cancers · doi:10.3390/cancers15215164 · Cited by 19
CDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 19
Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
Lee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 18
Self-citation
HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
Torrisi, R., Jacobs, F., Miggiano, C., Sanctis, R. D., & Santoro, A. (2023) · Drugs in Context · doi:10.7573/dic.2022-12-2 · Cited by 18
Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
Moukas, S. I., Kasimir‐Bauer, S., Tewes, M., Kolberg, H., Hoffmann, O., Kimmig, R., & Keup, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-47874-3 · Cited by 17
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
Palmieri, C., Musson, A., Harper-Wynne, C. L., Wheatley, D. A., Bertelli, G., Macpherson, I. R., Nathan, M., McDowall, E., Bhojwani, A. A., Verrill, M. W., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02352-5 · Cited by 17
Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population
Chen, B.-F., Tsai, Y., Chao, T., Lien, P., Lin, Y., Feng, C.-J., Chen, Y.-J., Cheng, H.-F., Liu, C., Lai, J., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01458-1 · Cited by 16
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Mai, N., dos Anjos, C. H., Razavi, P., Safonov, A. M., Patil, S., Chen, Y., Drago, J. Z., Modi, S., Bromberg, J., Dang, C. T., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00699-3 · Cited by 16
CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
Behrouzi, R., Armstrong, A. C., & Howell, S. J. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07035-6 · Cited by 15
Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers
Lashen, A., Alqahtani, S., Shoqafi, A., Algethami, M., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095053 · Cited by 13
Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer
Grammoustianou, Μ., Dimitrakopoulos, F.-I. D., & Koutras, A. K. (2024) · Cancers · doi:10.3390/cancers16101801 · Cited by 13
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial
Tripathy, D., Blum, J. L., Karuturi, M. S., McCune, S. L., Kurian, S., Moezi, M. M., Anderson, D., Gauthier, E. R., Zhang, Z., Montelongo, M. Z., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae291 · Cited by 12
Self-citation
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies
Vieira, C., Piperis, M., Sagkriotis, A., & Cottu, P. H. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103866 · Cited by 12
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
Mastrantoni, L., Orlandi, A., Palazzo, A., Garufi, G., Fabi, A., Daniele, G., Giannarelli, D., Tortora, G., & Bria, E. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101824 · Cited by 14
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
Zhao, J. J., Fong, K. Y., Chan, Y. H., Tey, J. C. S., Dawood, S. S., Lee, S. C., Finn, R. S., Sundar, R., & Lim, J. S. J. (2023) · Cancers · doi:10.3390/cancers15184558 · Cited by 12
Self-citation
Best of the year: Advanced breast cancer in 2023
Schlam, I. M., & Chávez‐MacGregor, M. (2024) · The Breast · doi:10.1016/j.breast.2024.103677 · Cited by 12
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
Goel, S., Jovanović, B., Chu, X., Hughes, M. E., Erick, T. K., Russo, D., DiLullo, M. K., Wrabel, E., Jeselsohn, R. M., Lin, N., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2647 · Cited by 11
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
Schlam, I. M., Giordano, A., & Tolaney, S. M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2288147 · Cited by 11
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
Schettini, F., Seguí, E., Conte, B., Sanfeliu, E., González‐Farré, B., Jares, P., Vidal‐Sicart, S., Ganau, S., Cebrecos, I., Brasó‐Maristany, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009352 · Cited by 11
CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
Zeng, N., Han, J., Liu, Z., He, J., Tian, K., & Chen, N. (2023) · Cancers · doi:10.3390/cancers15133386 · Cited by 10
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
Rugo, H. S., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Brufsky, A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad209 · Cited by 10
Self-citation
Recommendations for cyclin‑dependent kinase 4/6 inhibitor treatments in the context of co‑morbidity and drug interactions (Review)
Teomete, M., Çabuk, D., Korkmaz, T., Seber, S., Ozturk, O., Aver, B., Karaalp, A., & Başaran, G. (2024) · Oncology Letters · doi:10.3892/ol.2024.14278 · Cited by 10
Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
Raghavendra, A. S., Damodaran, S., Barcenas, C. H., Fuqua, S. A. W., Layman, R. M., & Tripathy, D. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70055 · Cited by 10
First‐line CDK4/6 inhibitor‐based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta‐analysis
Guo, X., Zhou, Y., Zhang, K., Lü, W., Zhong, X. Z., Wu, S., Shen, L., Chen, H., & Chen, Y. (2023) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12571 · Cited by 10
Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer
Baltussen, J. C., Mooijaart, S. P., Vulink, A. J. E., Houtsma, D., van der Deure, W. M., Westerman, E. M., Oosterkamp, H. M., Spierings, L. E. A. M. M., van den Bos, F., de Glas, N. A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07312-y · Cited by 10
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
Cameron, D., Sharma, V. K., Biswas, C., Clarke, C., Chandiwana, D., & Pathak, P. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2182051 · Cited by 10
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Kim, J., Shin, J., Ahn, J. S., Park, Y. H., & Im, Y. (2023) · Cancers · doi:10.3390/cancers15133431 · Cited by 10
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
Marta, G. N., Singer, C. F., Hlauschek, D., DeMichele, A. M., Tarantino, P., de Azambuja, E., Pfeiler, G., Martı́n, M., Balko, J. M., Nowecki, Z. I., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01899-2 · Cited by 9
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
Yıldırım, H. Ç., Kutlu, Y., Mutlu, E., Aykan, M. B., Korkmaz, M., Yalçın, S., Şakalar, T., Celayir, Ö. M., Kayıkçıoğlu, E., Aslan, F., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02460-5 · Cited by 9
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
Yıldırım, H. Ç., Kapar, C., Köksal, B., Seyyar, M., Sanci, P. C., Guliyev, M., Perkin, P., Büyükkör, M., Yaslıkaya, Ş., Majidova, N., et al. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2330835 · Cited by 9
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
Ferro, A., Generali, D., Caffo, O., Caldara, A., Lisi, D. D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., & Ciribilli, Y. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.002 · Cited by 9
CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
Akhade, A., Wambeke, S. V., & Gyawali, B. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.ed124 · Cited by 9
What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
Trapani, D., & Mayer, E. L. (2023) · Cancer · doi:10.1002/cncr.34672 · Cited by 9
Toxicity profiles of cyclin-dependent kinase 4/6 inhibitors: safety analysis from clinical trials and the FDA adverse event reporting system
Zhou, J., Lin, X., Wang, S., Xie, M., Hu, X., & Cai, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1673284 · Cited by 8
Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer
Würstlein, R., Kolberg, H., Hartkopf, A. D., Fehm, T. N., Welslau, M., Schütz, F., Fasching, P. A., Janni, W. J., Witzel, I., Thomssen, C., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2300-5326 · Cited by 8
Self-citation
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
Aktas, B., Fehm, T. N., Welslau, M., Müller, V., Lüftner, D., Schütz, F., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1912-7362 · Cited by 8
Self-citation
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases
Rader, R. K., Anders, C. K., Lin, N., & Sammons, S. L. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01086-z · Cited by 8
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
Villa, F., Crippa, A., Pelizzoni, D., Ardizzoia, A., Scartabellati, G., Corbetta, C., Cipriani, E., Lavitrano, M., & Ardizzoia, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914427 · Cited by 8
Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series
Albright, B. B., Shuey, S., Secord, A. A., Havrilesky, L. J., Berchuck, A., & Previs, R. A. (2023) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2023.101297 · Cited by 8
CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs
Schneeweiss, A., Brucker, S. Y., Huebner, H., Volmer, L. L., Hack, C. C., Seitz, K., Ruebner, M., Heublein, S., Thewes, V., Lüftner, D., et al. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2286-6066 · Cited by 8
Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China
Wu, X., Jin, N., Gao, H., Yan, M., Chen, Q., Sun, T., Hao, C., Zhao, Y., Han, X., Pan, Y., et al. (2023) · Cancers · doi:10.3390/cancers15174360 · Cited by 7
Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
Brufsky, A., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., & Rugo, H. S. (2023) · Cancers · doi:10.3390/cancers15215268 · Cited by 7
Self-citation
Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice
da Costa, F. A., Borges, F. C., Ramos, A., Mayer, A., Brito, C., Ramos, C., Bernardo, C., Cossito, M., Furtado, C. D., Ferreira, A. R., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01678-5 · Cited by 7
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending
Goldstein, D. A., Saltz, L. B., Pond, G. R., & Tannock, I. F. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000287 · Cited by 7
Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls
Wright, K., Mittal, A., & Gyawali, B. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000984 · Cited by 6
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2344-5269 · Cited by 6
Self-citation
Position paper on CDK4/6 inhibitors in early breast cancer
Gnant, M., Singer, C. F., Rinnerthaler, G., Pfeiler, G., Egle, D., Balić, M., & Bartsch, R. (2023) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00878-1 · Cited by 5
Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy
Schlefman, J., Brenin, C. M., Millard, T. A., & Dillon, P. M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02255-8 · Cited by 5
Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer
Lobo-Martins, S., Corredeira, P., Cavaco, A. C. M., Rodrigues, C., Piairo, P., Lopes, C., Fraga, J. S., da Silva, M. P., Alves, P., Szeneszi, L. W., et al. (2024) · Cells · doi:10.3390/cells13161391 · Cited by 5
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review
Benvenuti, C., Grinda, T., Rassy, E., Dixon-Douglas, J. R., Ribeiro, J. M., Zambelli, A., Santoro, A., & Pistilli, B. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01259-4 · Cited by 5
Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research
Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
Finn, R. S., Boér, K., Bondarenko, I., Patel, R., Pintér, T., Schmidt, M., Shparyk, Y. V., Thummala, A. R., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 179
Self-citation
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).
Finn, R. S., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. O., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1001 · Cited by 71
Self-citation
Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
Rugo, H. S., Finn, R., Dieras, V. C., Ettl, J., Lipatov, O. N., Joy, A. A., Harbeck, N., Castrellon, A. B., Lu, D., Mori, A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.sabcs17-p5-21-03 · Cited by 16
Self-citation
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05125-4 · Cited by 443
Self-citation
Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2
Rugo, H. S., Finn, R., Gelmon, K. A., Joy, A. A., Lipatov, O. N., Harbeck, N., Castrellon, A. B., Mukai, H., Walshe, J. M., Mori, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy272.322
Self-citation

Authors: Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., Walshe, J. M., Martin, M., Chavez Mac Gregor, M., Bananis, E., Gauthier, E. R., Lu, D. R., Kim, S., & Slamon, D. J.
Affiliations: University of California, Los Angeles (US)
University of California, San Francisco (US)
Centre Eugène Marquis (FR)
LMU Klinikum (DE)
Seoul National University (KR)
BC Cancer Agency (CA)
Cancer Trials Ireland (IE)
Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Universidad Complutense de Madrid, GEICAM Breast Cancer Group, Madrid, Spain;
The University of Texas MD Anderson Cancer Center, Houston, TX;
Pfizer (United States) (US)
ORCID: Finn, Richard S.
Rugo, Hope S.
Dieras, Veronique C
Harbeck, Nadia
Im, Seock-Ah
Gelmon, Karen A.
Walshe, Janice Maria
Bananis, Eustratios
Gauthier, Eric Roland
Lu, Dongrui Ray
Slamon, Dennis J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-06-10
Volume: 40
Issue: 17_suppl
Pages: LBA1003-LBA1003
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2022.40.17_suppl.lba1003
OpenAlex: W4293083647
Cited by: 169
References: 0
Citations by year: 2026: 9 · 2025: 19 · 2024: 52 · 2023: 79 · 2022: 10
Type: conference abstract
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: Pfizer Inc.
Topics: Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: palbociclib, letrozole, CDK4/6 inhibitors, estrogen receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, first-line therapy, overall survival, PALOMA-2, progression-free survival, aromatase inhibitors, postmenopausal women, endocrine therapy, hazard ratio, statistical power

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks